ICON Launches New Analytics Service For Advanced Medical Review Of Laboratory Data

Published: Nov 13, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Dublin, Ireland, 13 November, 2013 – ICON plc, (NASDAQ: ICLR) a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced ICONIK Labs, the latest service to leverage its ICONIK technology platform.

ICONIK Labs is an interactive analytics tool that allows Clinical and Medical team members to visualise, analyse and report on large volumes of laboratory data in real time. Using ICONIK Labs’ advanced visualisation capabilities, project teams can interact with data and view trends at any level of detail, including patient, site, study or across an entire program through a series of dynamic filters. ICONIK Labs enhances a study’s quality by instantly identifying sites with an unusual number of lab values outside the normal range and can also improve patient safety by providing Hy’s Law analysis which assists with the detection of subjects at risk of Drug Induced Liver Injury (DILI).

Commenting on the new service, Dr. Steve Cutler, Group President, ICON Clinical Research Services, said: “ICONIK Labs has transformed how study teams review and analyse laboratory data and has enabled a fresh approach to combining lab parameters to review study trends. It enables study teams to quickly uncover actionable insights that support earlier, more informed decision-making and more efficient trial management.”

ICONIK Labs is the latest service to leverage the ICONIK technology platform and follows ICON’s recent announcement of ICONIK Monitoring and ICONIK Patient Safety. ICONIK Monitoring is a new service that improves quality and reduces the costs of clinical development through more effective use of monitoring resources. ICONIK Patient Safety enables real-time analysis of aggregated patient safety data, giving study teams the ability to uncover potential medical issues in real-time.

This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov.

About ICON plc

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has approximately 10,300 employees, operating from 77 locations in 38 countries.

Further information is available at www.iconplc.com

ICON Media Contact

Genevieve Tuck

Weber Shandwick

Tel: +44 (0)20 7067 0655


Help employers find you! Check out all the jobs and post your resume.

Back to news